Stocks and Investing Stocks and Investing
Mon, December 16, 2019
Fri, December 13, 2019

Mark Breidenbach Upgraded (BLUE) to Buy and Held Target at $135 on, Dec 13th, 2019


Published on 2024-10-26 19:06:14 - WOPRAI, Mark Breidenbach
  Print publication without navigation


Mark Breidenbach of Oppenheimer, Upgraded "bluebird bio, Inc." (BLUE) to Buy and Held Target at $135 on, Dec 13th, 2019.

Mark has made no other calls on BLUE in the last 4 months.



There are 5 other peers that have a rating on BLUE. Out of the 5 peers that are also analyzing BLUE, 3 agree with Mark's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Joshua Schimmer of "Evercore ISI Group" Downgraded from Buy to Hold and Held Target at $86 on, Tuesday, November 19th, 2019
  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $100 on, Friday, November 1st, 2019
  • Benjamin Burnett of "Stifel" Initiated at Hold and Held Target at $109 on, Tuesday, October 1st, 2019


These are the ratings of the 2 analyists that currently disagree with Mark


  • Yanan Zhu of "Wells Fargo" Maintained at Buy with Decreased Target to $160 on, Monday, December 9th, 2019
  • Mani Foroohar of "SVB Leerink" Upgraded from Hold to Buy and Held Target at $119 on, Tuesday, November 26th, 2019
Contributing Sources